Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-Controlled, Phase 2b Study of ISIS 678354 in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Phase 2b Study of ISIS 678354 in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olezarsen (Primary)
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Acronyms Bridge-TIMI 73a
  • Sponsors Ionis Pharmaceuticals

    • Most Recent Events

    • 07 Apr 2024 According to an Ionis Pharmaceuticals media release, primary results of the Bridge-TIMI 73a Trial was presented at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia and published in The New England Journal of Medicine (NEJM).
    • 25 Mar 2024 According to Ionis Pharmaceuticals, Inc media release, the company will present primary results on April 7, 2024 at 8:30am ET during the session on Late-Breaking Clinical Trials II.
    • 22 Jan 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top